Medexus Pharmaceuticals Statistics

Total Valuation

MEDXF has a market cap or net worth of 68.54 million. The enterprise value is 101.71 million.

Market Cap	68.54M
Enterprise Value	101.71M

Important Dates

The next estimated earnings date is Monday, June 23, 2025.

Earnings Date	Jun 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	32.26M
Shares Outstanding	n/a
Shares Change (YoY)	+13.60%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	29.87M

Valuation Ratios

The trailing PE ratio is 19.24.

PE Ratio	19.24
Forward PE	n/a
PS Ratio	0.63
PB Ratio	2.07
P/TBV Ratio	n/a
P/FCF Ratio	2.95
P/OCF Ratio	2.93
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.57, with an EV/FCF ratio of 4.38.

EV / Earnings	28.56
EV / Sales	0.88
EV / EBITDA	4.57
EV / EBIT	6.42
EV / FCF	4.38

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.21.

Current Ratio	1.01
Quick Ratio	0.34
Debt / Equity	1.21
Debt / EBITDA	1.89
Debt / FCF	1.72
Interest Coverage	1.79

Financial Efficiency

Return on equity (ROE) is 11.37% and return on invested capital (ROIC) is 12.14%.

Return on Equity (ROE)	11.37%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	12.14%
Return on Capital Employed (ROCE)	18.88%
Revenue Per Employee	1.34M
Profits Per Employee	43,439
Employee Count	82
Asset Turnover	0.72
Inventory Turnover	1.50

Taxes

In the past 12 months, MEDXF has paid 318,981 in taxes.

Income Tax	318,981
Effective Tax Rate	303.85%

Stock Price Statistics

The stock price has increased by +79.66% in the last 52 weeks. The beta is 2.04, so MEDXF's price volatility has been higher than the market average.

Beta (5Y)	2.04
52-Week Price Change	+79.66%
50-Day Moving Average	1.88
200-Day Moving Average	1.99
Relative Strength Index (RSI)	59.21
Average Volume (20 Days)	8,453

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MEDXF had revenue of 109.54 million and earned 3.56 million in profits. Earnings per share was 0.14.

Revenue	109.54M
Gross Profit	63.41M
Operating Income	15.04M
Pretax Income	3.19M
Net Income	3.56M
EBITDA	20.96M
EBIT	15.04M
Earnings Per Share (EPS)	0.14

Full Income Statement

Balance Sheet

The company has 8.44 million in cash and 39.91 million in debt, giving a net cash position of -31.47 million.

Cash & Cash Equivalents	8.44M
Total Debt	39.91M
Net Cash	-31.47M
Net Cash Per Share	n/a
Equity (Book Value)	33.10M
Book Value Per Share	1.34
Working Capital	368,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 23.37 million and capital expenditures -132,000, giving a free cash flow of 23.23 million.

Operating Cash Flow	23.37M
Capital Expenditures	-132,000
Free Cash Flow	23.23M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 57.89%, with operating and profit margins of 13.73% and 3.25%.

Gross Margin	57.89%
Operating Margin	13.73%
Pretax Margin	2.91%
Profit Margin	3.25%
EBITDA Margin	19.13%
EBIT Margin	13.73%
FCF Margin	21.21%

Dividends & Yields

MEDXF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.60%
Shareholder Yield	n/a
Earnings Yield	5.20%
FCF Yield	33.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.

Last Split Date	Dec 19, 2018
Split Type	Reverse
Split Ratio	0.0666666

Scores

MEDXF has an Altman Z-Score of 0.71 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.71
Piotroski F-Score	3